New Wave of Targeted and Immune Therapies Reshapes Marginal Zone Lymphoma Care

Marginal zone lymphoma has long occupied an awkward corner of hematology. It is a family of indolent B-cell cancers, generally slow-growing and often manageable for years, yet it stubbornly resists a one-size-fits-all approach. A new open-access review published in Annals of Hematology by Xin Wang, Qiang Xiong, Yulan Zhou, Min Yu, and Fei Li of Nanchang University maps the rapidly shifting therapeutic landscape of this disease, drawing together the molecular discoveries and clinical advances that are now redefining how clinicians think about treatment. The review arrives at a moment when the field is moving decisively beyond conventional immunochemotherapy toward agents designed to strike the specific molecular vulnerabilities of the malignant B cell.

The starting point for this transformation is a sober clinical reality. Although most patients with marginal zone lymphoma experience favorable outcomes, approximately twenty percent relapse or progress early, within twenty-four months of initial treatment. That minority represents the central unsolved problem in the field. For these patients, the disease often reveals a more aggressive biology than its indolent label suggests, and the therapeutic options available after frontline therapy have historically been limited. It is precisely this population that the new generation of targeted and immune-based therapies aims to serve, and the review places their needs at the center of its analysis.

What has made precision medicine possible in this disease is the accumulation of detailed molecular profiling. The authors describe recurrent alterations in three major signaling axes: the B-cell receptor pathway, the NF-κB pathway, and NOTCH signaling. These are not random findings. Chronic antigen drive through the B-cell receptor, constitutive activation of NF-κB-dependent survival programs, and dysregulated NOTCH signaling together form the wiring diagram of the malignant marginal zone B cell. Layered on top of these are epigenetic changes that alter gene expression without changing the underlying DNA sequence, as well as abnormalities in the immune microenvironment that surrounds and supports the tumor. Each of these layers offers a potential point of therapeutic intervention, and each has spawned a corresponding class of drugs now in clinical evaluation.

Among the targeted agents, the strongest clinical evidence belongs to Bruton tyrosine kinase inhibitors, known as BTK inhibitors. BTK is a signaling molecule essential to B-cell receptor function, and blocking it effectively starves the malignant cell of one of its principal survival signals. In relapsed or refractory marginal zone lymphoma, these agents have produced durable responses and have become a cornerstone of second-line and later therapy. The review emphasizes, however, that their use is not without complications. First-generation BTK inhibitors carry risks of atrial arrhythmias, bleeding, and hypertension, and resistance can emerge through mutations in BTK itself or in downstream signaling components. Newer, more selective inhibitors aim to retain efficacy while narrowing the toxicity profile, and the choice of agent increasingly depends on patient comorbidities and treatment goals.

Beyond BTK inhibition, the review surveys two additional classes of small-molecule targeted therapy. BCL-2 inhibitors exploit a different vulnerability: the overexpression of an anti-apoptotic protein that allows lymphoma cells to evade programmed cell death. By releasing the mitochondrial brake on apoptosis, these agents can trigger tumor cell death directly, and they have been evaluated across B-cell malignancies with growing interest in marginal zone lymphoma. PI3K inhibitors, meanwhile, target a lipid kinase downstream of the B-cell receptor that promotes cell survival, proliferation, and trafficking. Their clinical history in indolent lymphomas has been complicated by immune-mediated toxicities, including colitis and pneumonitis, which has prompted closer regulatory scrutiny and a more careful approach to patient selection. The review stresses that efficacy must always be weighed against these safety considerations, particularly in an indolent disease where patients may live with treatment consequences for decades.

Monoclonal antibodies remain a foundational element of the therapeutic arsenal, and the review highlights how this class continues to evolve. Antibodies directed against CD20 have long formed the backbone of frontline treatment, and novel antibodies with enhanced immune-recruiting properties are extending this approach. Antibody-drug conjugates represent a further refinement, coupling the targeting specificity of an antibody to a potent cytotoxic payload that is released only after the drug reaches the tumor cell. This design concentrates chemotherapy’s killing power where it is needed while limiting collateral damage to healthy tissue. The result is a class of agents that blurs the traditional line between targeted therapy and cytotoxic treatment, offering a middle path with distinct pharmacological logic.

Perhaps the most striking advances described in the review lie in the realm of immune-based therapeutics. Bispecific antibodies are engineered molecules capable of binding two targets simultaneously: one arm attaches to a marker on the malignant B cell, while the other engages CD3 on T cells, physically bridging the two and forcing the immune system to attack the tumor. These off-the-shelf agents have demonstrated impressive activity in other indolent lymphomas and are being evaluated in marginal zone lymphoma across treatment settings. Chimeric antigen receptor T-cell therapy, or CAR-T, takes a different route to the same goal. A patient’s own T cells are harvested, genetically engineered to recognize a B-cell antigen such as CD19, expanded in the laboratory, and reinfused. The engineered cells then hunt down and destroy lymphoma cells throughout the body. For patients whose disease has failed multiple prior lines of therapy, these cellular and bispecific approaches have opened doors that simply did not exist a decade ago.

The review is careful to frame these advances within their limitations. Clinical evidence for several of the newer modalities in marginal zone lymphoma specifically remains less mature than in other B-cell malignancies, and the heterogeneity of the disease itself complicates interpretation. Marginal zone lymphoma encompasses distinct subtypes arising in different anatomical sites, from the stomach to the spleen to the lymph nodes, each with its own biology and treatment considerations. Extrapolating results from one subtype or from related lymphomas carries genuine uncertainty. The authors also emphasize the importance of biomarkers: molecular alterations identified at diagnosis or relapse may eventually guide which patients benefit from which agents, but validated predictive markers remain an aspiration rather than a routine clinical reality for many of these drugs.

Questions of treatment sequencing loom large over the entire field. With BTK inhibitors, BCL-2 inhibitors, PI3K inhibitors, antibody-based approaches, bispecifics, and CAR-T all now available or in development, clinicians face an increasingly complex decision tree. Should a novel targeted agent be deployed at first relapse, or should conventional therapy be exhausted first? Can immune-based approaches such as bispecific antibodies or CAR-T be moved earlier in the disease course, where patients may be fitter and more likely to tolerate them? How should resistance to one class of agent influence the choice of the next? The review addresses these questions directly, arguing that rational sequencing, informed by molecular profiling and by the toxicity profiles of successive therapies, will be essential to maximizing the benefit each approach can deliver over a patient’s lifetime.

What emerges from this comprehensive synthesis is a portrait of a disease in transition. Marginal zone lymphoma, once treated with a relatively blunt toolkit, is becoming a testing ground for the full breadth of modern cancer therapeutics, from kinase inhibitors that rewire intracellular signaling to engineered immune cells that patrol the body seeking malignant targets. The molecular alterations that drive the disease, in B-cell receptor, NF-κB, and NOTCH pathways, in the epigenome, and in the tumor microenvironment, are no longer merely descriptive findings; they are the blueprint for drug development. For the majority of patients who do well with current therapy, these advances promise more tailored and less toxic options when treatment is needed. For the twenty percent who relapse early, they represent something more consequential: a genuine expansion of hope, grounded in a deeper understanding of what keeps their cancer alive and how to take it apart.

Subject of Research: Targeted and immunotherapeutic strategies for marginal zone lymphoma

Article Title: Emerging frontiers in targeted and immunotherapeutic strategies for marginal zone lymphoma

Article References: Wang, X., Xiong, Q., Zhou, Y., Yu, M., & Li, F. (2026). Emerging frontiers in targeted and immunotherapeutic strategies for marginal zone lymphoma. Annals of Hematology. https://doi.org/10.1007/s00277-026-07288-3

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07288-3

Keywords: marginal zone lymphoma, BTK inhibitors, BCL-2 inhibitors, PI3K inhibitors, bispecific antibodies, CAR-T therapy, immunotherapy, targeted therapy, NF-κB signaling, NOTCH signaling, B-cell lymphoma, antibody-drug conjugates